# Biocryst Pharmaceuticals Inc.

Canonical: https://abierto.us/vendors/biocryst-pharmaceuticals-inc-mgxadj6sclj5

- UEI: MGXADJ6SCLJ5
- CAGE: 4GBX7
- Location: Durham, NC
- Awards in window: 18 (40 transactions), -$26,127,043 obligated, February 16, 2024 to September 3, 2026

## Awarding agencies

- Department of Veterans Affairs: 14 awards, $2,162,057
- National Institutes of Health: 1 awards, -$3,711,828
- Office of Assistant Secretary for Preparedness and Response: 3 awards, -$24,577,272

## Industries

- 325412 Pharmaceutical Preparation Manufacturing: $16,039,731
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): -$3,711,828
- 541711 Professional, Scientific, and Technical Services: -$8,587,497
- 541710 Professional, Scientific, and Technical Services: -$29,867,448

## Competition

- Full and Open Competition: 18 awards

## Solicitations won

- Peramivir (RAPIVAB (peramivir injection) (75A50324F80012-LSJ). https://abierto.us/opportunities/75a50324f80012lsj
- Peramivir (RAPIVAB (peramivir injection) (75A50324Q00006), $69,388,369. https://abierto.us/opportunities/75a50324q00006

## Largest awards

- 75A50324F80012 (delivery order): $13,877,674, Aspr/Orm-Sns. Peramivir (Rapivab 200mg/20ml (10mg/Ml Inj Soln)). https://www.usaspending.gov/award/CONT_AWD_75A50324F80012_7505_36F79721D0166_3600/
- 36C26025F0024 (delivery order): $379,939, 260-Network Contract Office 20. Berotralstat HCL 150MG Cap,oral (Orladeyo).. https://www.usaspending.gov/award/CONT_AWD_36C26025F0024_3600_36F79721D0166_3600/
- 36C26024F0625 (delivery order): $379,349, 260-Network Contract Office 20. Berotralstat HCL 150MG Cap,oral Trade Name: Orladeyo 150MG Cap. https://www.usaspending.gov/award/CONT_AWD_36C26024F0625_3600_36F79721D0166_3600/
- 36C26026F0006 (delivery order): $360,000, 260-Network Contract Office 20. Pharm - Orladeyo. https://www.usaspending.gov/award/CONT_AWD_36C26026F0006_3600_36F79721D0166_3600/
- 36C26024F0270 (delivery order): $357,245, 260-Network Contract Office 20. Bulk Order Orladeyo. https://www.usaspending.gov/award/CONT_AWD_36C26024F0270_3600_36F79721D0166_3600/
- 36C26025F0070 (delivery order): $242,987, 260-Network Contract Office 20. Bulk Orladeyo Pharmaceutical. https://www.usaspending.gov/award/CONT_AWD_36C26025F0070_3600_36F79721D0166_3600/
- 36C26024F0258 (delivery order): $201,722, 260-Network Contract Office 20. Orladeyo 150MG Caps. https://www.usaspending.gov/award/CONT_AWD_36C26024F0258_3600_36F79721D0166_3600/
- 36C26026F0294 (delivery order): $151,465, 260-Network Contract Office 20. Orladeyo 150MG Cap. https://www.usaspending.gov/award/CONT_AWD_36C26026F0294_3600_36F79721D0166_3600/
- 36C24926F0152 (delivery order): $30,293, 249-Network Contract Office 9. Emergency Orladeyo. https://www.usaspending.gov/award/CONT_AWD_36C24926F0152_3600_36F79721D0166_3600/
- 36C26024F0240 (delivery order): $29,650, 260-Network Contract Office 20. Orladeyo Emergent. https://www.usaspending.gov/award/CONT_AWD_36C26024F0240_3600_36F79721D0166_3600/
- 36C26025F0296 (delivery order): $29,408, 260-Network Contract Office 20. Bulk Order Orladeyo for Veteran Care.. https://www.usaspending.gov/award/CONT_AWD_36C26025F0296_3600_36F79721D0166_3600/
- 36C26124N0446 (delivery order): $0, 261-Network Contract Office 21. Berotralstat. https://www.usaspending.gov/award/CONT_AWD_36C26124N0446_3600_36F79721D0166_3600/
- 36E79721A0015: $0, Nac Pharmaceuticals. Exercise Option Year 3. https://www.usaspending.gov/award/CONT_IDV_36E79721A0015_3600/
- 36E79726A0015: $0, Nac Pharmaceuticals. BPA for Orladeyo and Rapivab. https://www.usaspending.gov/award/CONT_IDV_36E79726A0015_3600/
- 36F79721D0166: $0, Nac Federal Supply Schedule. Public Law 2025. https://www.usaspending.gov/award/CONT_IDV_36F79721D0166_3600/
- 75N93020C00055 (definitive contract): -$3,711,828, National Institutes of Health Niaid. Extend Period of Performance for the Base Till September 30, 2022. (Note: the Modification P00003 Is Modification P00002 in the NBS System, Modification P00004 Is Modification P00003 in the NBS System and These Are Clarifications for Audit Purposes. https://www.usaspending.gov/award/CONT_AWD_75N93020C00055_7529_-NONE-_-NONE-/
- HHSO100201500007C (definitive contract): -$8,587,497, Barda - Aspr / Daappo / Barda DCMA. De-Obligate Canceling Funds.. https://www.usaspending.gov/award/CONT_AWD_HHSO100201500007C_7505_-NONE-_-NONE-/
- HHSO100200700032C (definitive contract): -$29,867,448, Barda - Aspr / Daappo / Barda DCMA. Modification 12. https://www.usaspending.gov/award/CONT_AWD_HHSO100200700032C_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/biocryst-pharmaceuticals-inc-mgxadj6sclj5.